BMS cancer drug receives FDA nod

The latest stories trending on MedCity News.

Editor's Pick

Top Story BMS Cancer Drug's New FDA Nod Puts It on Path to Reach Blockbuster Status Bristol Myers Squibb drug Reblozyl is now approved as a first-line therapy for anemia caused by myelodysplastic syndromes, a group of blood cancers. It's the third indication for the drug, which analysts project could top $4 billion in peak sales. Sponsored Content Importance of Patient Capital in Life Sciences Presented by TSX Venture Exchange TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development purposes. Learn More>> Tell Us What You Think If you haven't taken 3-5 minutes to tell us what you think yet, please do. We value your input and want to know how we can serve you better. Share your preferences, insights, and feedback. Thank you for your time. Share Feedback

Featured News

5 Ways NLP AI Technology is Driving Value for Providers Today Don't bet so big on AI solutions with "someday potential" that you ignore tools that can solve challenges and generate ROI now. Here are five critical AI investments that provide "right now" value for health systems, clinicians and patients. Hospitals' Operating Margins Fell In July After 4 Months of Growth Hospital finances worsened in July as volumes dropped, according to a new report. Following four months of growth, hospitals' median year-to-date operating margin index fell 1.3%, down from 1.4% in June. Hospital finances still remained in a better place than they were last year, given hospitals' median operating margins were -0.98% in July 2022. Apellis Lays Off 25% of Staff and Turns Focus to Commercializing New Eye Drug The Apellis Pharmaceuticals restructuring will save up to $300 million. It comes as the biotech continues its inquiry into the cause of a rare inflammatory complication reported in a small number of patients who received its geographic atrophy drug, Syfovre. Study On Teen Mental Health App Shows High Engagement, Positive Impact A study on BeMe Health, a behavioral health platform for teens, found that users engaged with the platform eight times on average over a month. The study was done in collaboration with Stanford University. Technology is Great. But Does it Really Change Health Outcomes for the Better? We must advocate for the positive impact that technology can have on healthcare outcomes, while also building solutions to create a more equitable health system. This includes traditional, less tech-reliant methods for those unable to embrace technology. At-Home Physical Therapy Leads to Better Recovery in Post-Surgical Patients, Study Shows Luna — an at-home physical therapy provider — released a new study on the efficacy of its post-surgery rehabilitation program. The study, which was conducted by the startup, showed that the Luna Pathways program did a good job of reducing patients' pain, increasing care plan adherence, and decreasing avoidable hospital readmissions and emergency department visits. HHS Drops First 10 Drugs for Medicare Drug Price Negotiation HHS released the first 10 drugs selected for the Medicare Drug Price Negotiation Program. These drugs include Eliquis, Jardiance and Xarelto. Under the program, the federal government will be able to negotiate the price for selected drugs for the first time.

Resources

The Future of Healthcare CIOs Learn how successful CIOs are adapting to challenging times and how they might shift their roles in response to exciting innovation in the years to come. Download Now

MedCity News • PO Box 901 • New York, NY unsubscribe